Atrium Therapeutics Funding: $50M Round (Oct 2026)

Recent changes

Oct 10, 2026Oct 10, 2026Raised $50M Pulse 2.0
Oct 10, 2026Oct 10, 2026New investor: Casdin Capital Pulse 2.0
Oct 10, 2026Oct 10, 2026Atrium Therapeutics Raises $50M For Heart Drugs Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Oct 10, 2026	funding round	$50M	—	Casdin CapitalunverifiedSirenia Capital ManagementAberdeen InvestmentsMontanovaSessa Capital	Pulse 2.0

Investors

Casdin Capital

Latest Pulse

Oct 10, 2026Atrium Therapeutics Raises $50M For Heart DrugsAtrium Therapeutics raised a $50 million private placement priced at market to fund two RNA-therapy programs for rare heart conditions through 2028.→

Coverage Timeline

newest first

Oct 10, 2026FUNDINGAtrium Therapeutics Raises $50M For Heart Drugs$50M Private Placement→

All Coverage

FUNDING· Oct 10, 2026

Atrium Therapeutics Raises $50M For Heart Drugs

FUNDING$50M Private Placement

Atrium Therapeutics Raises $50M For Heart Drugs

Atrium Therapeutics raised a $50 million private placement priced at market to fund two RNA-therapy programs for rare heart conditions through 2028.

Oct 10, 2026DEEP DIVE

Related Companies

Same sector

Scribe Therapeutics Attovia Therapeutics Apnimed Retension Pharmaceuticals Braveheart Bio Eli Lilly

Atrium Therapeutics FAQ

Who are Atrium Therapeutics's investors?

Atrium Therapeutics's investors include Casdin Capital.

Sources & methodologyshow

Where these figures come from

Pulse 2.0Value Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction